{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:53:03Z","timestamp":1791827583212,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["In Vitro Cell.Dev.Biol.-Animal"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11626-026-01196-6","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:31:41Z","timestamp":1783693901000},"page":"1052-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RMI2 knockdown suppresses ovarian cancer cell growth by impairing DNA damage repair via the ATR\/CHK1 signaling pathway"],"prefix":"10.1007","volume":"62","author":[{"given":"Kean","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"1196_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923508","volume":"12","author":"M Bagnoli","year":"2022","unstructured":"Bagnoli M, Nicoletti R, Valitutti M, Rizzo A, Napoli A, Montalvao De Azevedo R, Tomassetti A, Mezzanzanica D (2022) Impairment of RAD17 functions by miR-506-3p as a novel synthetic lethal approach targeting DNA repair pathways in ovarian cancer. Front Oncol 12:923508","journal-title":"Front Oncol"},{"key":"1196_CR2","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ncb3415","volume":"18","author":"TE Bass","year":"2016","unstructured":"Bass TE, Luzwick JW, Kavanaugh G, Carroll C, Dungrawala H, Glick GG, Feldkamp MD, Putney R, Chazin WJ, Cortez D (2016) ETAA1 acts at stalled replication forks to maintain genome integrity. Nat Cell Biol 18:1185\u20131195","journal-title":"Nat Cell Biol"},{"key":"1196_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/toxsci\/kfw103","volume":"153","author":"CL Browning","year":"2016","unstructured":"Browning CL, Qin Q, Kelly DF, Prakash R, Vanoli F, Jasin M, Wise JP Sr. (2016) Prolonged particulate hexavalent chromium exposure suppresses homologous recombination repair in human lung cells. Toxicol Sci 153:70\u201378","journal-title":"Toxicol Sci"},{"key":"1196_CR4","doi-asserted-by":"crossref","unstructured":"Caruso G, Weroha SJ, Cliby W (2025) Ovarian cancer: a review. JAMA 334:1278\u20131291","DOI":"10.1001\/jama.2025.9495"},{"key":"1196_CR5","doi-asserted-by":"crossref","unstructured":"Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R (2021) PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: four case reports. Mol Med Rep 23:75","DOI":"10.3892\/mmr.2020.11713"},{"key":"1196_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1029976","volume":"12","author":"E de Bree","year":"2022","unstructured":"de Bree E, Michelakis D, Anagnostopoulou E (2022) The current role of secondary cytoreductive surgery for recurrent ovarian cancer. Front Oncol 12:1029976","journal-title":"Front Oncol"},{"key":"1196_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86490-x","volume":"11","author":"JP Ditano","year":"2021","unstructured":"Ditano JP, Donahue KL, Tafe LJ, McCleery CF, Eastman A (2021) Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction. Sci Rep 11:7077","journal-title":"Sci Rep"},{"key":"1196_CR8","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ygyno.2020.08.035","volume":"159","author":"K Fuh","year":"2020","unstructured":"Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A (2020) Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol 159:877\u2013886","journal-title":"Gynecol Oncol"},{"key":"1196_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10565-021-09640-x","volume":"39","author":"A Ghelli Luserna Di Rora","year":"2023","unstructured":"Ghelli Luserna Di Rora A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G (2023) Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. Cell Biol Toxicol 39:795\u2013811","journal-title":"Cell Biol Toxicol"},{"key":"1196_CR10","doi-asserted-by":"crossref","unstructured":"Gralewska P, Gajek A, Rybaczek D, Marczak A, Rogalska A (2022) The influence of PARP, ATR, CHK1 inhibitors on premature mitotic entry and genomic instability in high-grade serous BRCA(MUT) and BRCA(WT) ovarian cancer cells. Cells 11:1889","DOI":"10.3390\/cells11121889"},{"key":"1196_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.09.003","volume":"71","author":"B Haynes","year":"2018","unstructured":"Haynes B, Murai J, Lee JM (2018) Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev 71:1\u20137","journal-title":"Cancer Treat Rev"},{"key":"1196_CR12","doi-asserted-by":"crossref","unstructured":"Hodson C, Low JKK, van Twest S, Jones SE, Swuec P, Murphy V, Tsukada K, Fawkes M, Bythell-Douglas R, Davies A, Holien JK, O\u02bcRourke JJ, Parker BL, Glaser A, Parker MW, Mackay JP, Blackford AN, Costa A, Deans AJ (2022) Mechanism of Bloom syndrome complex assembly required for double Holliday junction dissolution and genome stability. Proc Natl Acad Sci U S A 119:e2109093119","DOI":"10.1073\/pnas.2109093119"},{"key":"1196_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1101\/gad.349431.122","volume":"36","author":"JL Hopkins","year":"2022","unstructured":"Hopkins JL, Lan L, Zou L (2022) DNA repair defects in cancer and therapeutic opportunities. Genes Dev 36:278\u2013293","journal-title":"Genes Dev"},{"key":"1196_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1448789","volume":"12","author":"Z Kamaliyan","year":"2024","unstructured":"Kamaliyan Z, Clarke TL (2024) Zinc finger proteins: guardians of genome stability. Front Cell Dev Biol 12:1448789","journal-title":"Front Cell Dev Biol"},{"key":"1196_CR15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e70","volume":"31","author":"S Kehoe","year":"2020","unstructured":"Kehoe S (2020) FIGO staging in ovarian carcinoma and histological subtypes. J Gynecol Oncol 31:e70","journal-title":"J Gynecol Oncol"},{"key":"1196_CR16","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F (2017) Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res 23:3097\u20133108","journal-title":"Clin Cancer Res"},{"key":"1196_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.hoc.2018.07.006","volume":"32","author":"PA Konstantinopoulos","year":"2018","unstructured":"Konstantinopoulos PA, Matulonis UA (2018) Targeting DNA damage response and repair as a therapeutic strategy for ovarian cancer. Hematol Oncol Clin North Am 32:997\u20131010","journal-title":"Hematol Oncol Clin North Am"},{"key":"1196_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/bs.mcb.2022.12.018","volume":"182","author":"V Lebrec","year":"2024","unstructured":"Lebrec V, Gavet O (2024) Monitoring Chk1 kinase activity dynamics in live single cell imaging assays. Methods Cell Biol 182:221\u2013236","journal-title":"Methods Cell Biol"},{"key":"1196_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10238-021-00742-8","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, He X, Zhang X, Xu Y, Chen W, Liu X, Xu X (2022) RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. Clin Exp Med 22:229\u2013243","journal-title":"Clin Exp Med"},{"key":"1196_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-020-0873-4","volume":"22","author":"M Lightfoot","year":"2020","unstructured":"Lightfoot M, Montemorano L, Bixel K (2020) PARP inhibitors in gynecologic cancers: what is the next big development? Curr Oncol Rep 22:29","journal-title":"Curr Oncol Rep"},{"key":"1196_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/fcp.12834","volume":"37","author":"C Lin","year":"2023","unstructured":"Lin C, Liu P, Shi C, Qiu L, Shang D, Lu Z, Tu Z, Liu H (2023) Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. Fundam Clin Pharmacol 37:194\u2013214","journal-title":"Fundam Clin Pharmacol"},{"key":"1196_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7243146","volume":"2022","author":"S Lin","year":"2022","unstructured":"Lin S, Tian J, He Q, Yang M, Chen Z, Belogurov AA Jr., Li X, Zhang F, Liu Y, Chen G (2022) SN-38 sensitizes BRCA-proficient ovarian cancers to PARP inhibitors through inhibiting homologous recombination repair. Dis Markers 2022:7243146","journal-title":"Dis Markers"},{"key":"1196_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.canlet.2016.09.024","volume":"383","author":"AJ Massey","year":"2016","unstructured":"Massey AJ (2016) Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy. Cancer Lett 383:41\u201352","journal-title":"Cancer Lett"},{"key":"1196_CR24","doi-asserted-by":"publisher","first-page":"102655","DOI":"10.1016\/j.dnarep.2019.102655","volume":"81","author":"TN Moiseeva","year":"2019","unstructured":"Moiseeva TN, Bakkenist CJ (2019) Dormant origin signaling during unperturbed replication. DNA Repair (Amst) 81:102655","journal-title":"DNA Repair (Amst)"},{"key":"1196_CR25","doi-asserted-by":"crossref","unstructured":"Papageorgiou D, Liouta G, Pliakou E, Zachariou E, Sapantzoglou I, Prokopakis I, Kontomanolis EN (2025) Management of advanced ovarian cancer: current clinical practice and future perspectives. Biomedicines 13:1525","DOI":"10.3390\/biomedicines13071525"},{"key":"1196_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pilie","year":"2019","unstructured":"Pilie PG, Tang C, Mills GB, Yap TA (2019) State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 16:81\u2013104","journal-title":"Nat Rev Clin Oncol"},{"key":"1196_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1474337","volume":"15","author":"J Qian","year":"2024","unstructured":"Qian J, Liao G, Chen M, Peng RW, Yan X, Du J, Huang R, Pan M, Lin Y, Gong X, Xu G, Zheng B, Chen C, Yang Z (2024) Advancing cancer therapy: new frontiers in targeting DNA damage response. Front Pharmacol 15:1474337","journal-title":"Front Pharmacol"},{"key":"1196_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","volume":"126","author":"Z Qiu","year":"2018","unstructured":"Qiu Z, Oleinick NL, Zhang J (2018) ATR\/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450\u2013464","journal-title":"Radiother Oncol"},{"key":"1196_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson DL, Eskander RN, O\u2019Malley DM (2023) Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol 9:851\u2013859","journal-title":"JAMA Oncol"},{"key":"1196_CR30","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"1196_CR31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","volume":"131","author":"HL Smith","year":"2024","unstructured":"Smith HL, Willmore E, Prendergast L, Curtin NJ (2024) ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. Br J Cancer 131:905\u2013917","journal-title":"Br J Cancer"},{"key":"1196_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102802","volume":"299","author":"MM Soniat","year":"2023","unstructured":"Soniat MM, Nguyen G, Kuo HC, Finkelstein IJ (2023) The MRN complex and topoisomerase IIIa-RMI1\/2 synchronize DNA resection motor proteins. J Biol Chem 299:102802","journal-title":"J Biol Chem"},{"key":"1196_CR33","doi-asserted-by":"publisher","first-page":"9109","DOI":"10.1093\/nar\/gkaa631","volume":"48","author":"X Sun","year":"2020","unstructured":"Sun X, Wang Y, Ji K, Liu Y, Kong Y, Nie S, Li N, Hao J, Xie Y, Xu C, Du L, Liu Q (2020) NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest. Nucleic Acids Res 48:9109\u20139123","journal-title":"Nucleic Acids Res"},{"key":"1196_CR34","doi-asserted-by":"crossref","unstructured":"van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N (2021) Homologous recombination repair deficiency and implications for tumor immunogenicity. Cancers (Basel) 13:2249","DOI":"10.3390\/cancers13092249"},{"key":"1196_CR35","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, Domchek SM, Drapkin R, Shih IM, Brown EJ, Hwang WT, Armstrong DK, Gaillard S, Giuntoli R, Simpkins F (2023) Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) Trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin Cancer Res 29:2800\u20132807","journal-title":"Clin Cancer Res"},{"key":"1196_CR36","doi-asserted-by":"crossref","unstructured":"Yang L, Xie HJ, Li YY, Wang X, Liu XX, Mai J (2022) Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer (Review). Oncol Rep 47:82","DOI":"10.3892\/or.2022.8293"},{"key":"1196_CR37","doi-asserted-by":"crossref","unstructured":"Yu TJ, Yen CY, Cheng YB, Yen CH, Jeng JH, Tang JY, Chang HW (2022) Physapruin a enhances DNA damage and inhibits DNA repair to suppress oral cancer cell proliferation. Int J Mol Sci 23:8839","DOI":"10.3390\/ijms23168839"},{"key":"1196_CR38","doi-asserted-by":"publisher","first-page":"8331","DOI":"10.1002\/cam4.5533","volume":"12","author":"L Zhang","year":"2023","unstructured":"Zhang L, Hao C, Han B, Zeng G, Han L, Cao C, Liu H, Zhong Z, Zhao X, Wang J, Zhang Q (2023) RMI2 is a novel prognostic and predictive biomarker for breast cancer. Cancer Med 12:8331\u20138350","journal-title":"Cancer Med"},{"key":"1196_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109661","volume":"123","author":"F Zheng","year":"2020","unstructured":"Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H (2020) Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed Pharmacother 123:109661","journal-title":"Biomed Pharmacother"}],"container-title":["In Vitro Cellular & Developmental Biology - Animal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11626-026-01196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11626-026-01196-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11626-026-01196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:37:59Z","timestamp":1791826679000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11626-026-01196-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1007\/s11626-026-01196-6","relation":{},"ISSN":["1071-2690","1543-706X"],"issn-type":[{"value":"1071-2690","type":"print"},{"value":"1543-706X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}